Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany

Galin Michailov (), Glenn Davies and Karl Krobot

The European Journal of Health Economics, 2012, vol. 13, issue 3, pages 365-374

Keywords: Cost-effectiveness; Dyslipidaemia; Extended-release niacin; Hypercholesterolaemia; Laropiprant; Simvastatin; I10 (search for similar items in EconPapers)
Date: 2012
References: Add references at CitEc
Citations Track citations by RSS feed

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-011-0309-z (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:spr:eujhec:v:13:y:2012:i:3:p:365-374

Ordering information: This journal article can be ordered from
http://link.springer.de/orders.htm

Access Statistics for this article

The European Journal of Health Economics is edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer
Series data maintained by Guenther Eichhorn ().